Bicycle Therapeutics (BCYC) Enterprise Value (2019 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Enterprise Value data on file, last reported at -$510.1 million in Q2 2026.

• Quarterly Enterprise Value rose 29.3% year-over-year to -$510.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$510.1 million (up 29.3% YoY) and the FY2025 annual result came in at -$628.1 million, up 28.58% from the prior year.
• Enterprise Value rose to -$510.1 million in Q2 2026, from -$559.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$293.8 million in Q1 2023 to a low of -$961.4 million in Q2 2024.
• A 5-year average of -$570.2 million and a median of -$543.0 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value sank 182.39% — and 2026, when it rose 29.44%.
• Tracing BCYC's Enterprise Value over 5 years: stood at -$339.2 million in 2022, then plunged by 55.22% to -$526.4 million in 2023, then sank by 67.07% to -$879.5 million in 2024, then advanced by 28.58% to -$628.1 million in 2025, then gained by 18.79% to -$510.1 million in 2026.
• The last three Enterprise Value figures came in at -$510.1 million (Q2 2026), -$559.5 million (Q1 2026), and -$628.1 million (Q4 2025), per Business Quant data.